Iradimed Corp
IRMD Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$85.82
KIRA · Stoqly’s AI analyst, in plain words
- Iradimed Corp had $83.8M of revenue in fiscal 2025, up 14.4% on the year before. Over five years, revenue changed +21.5% a year on average.
- Its operating margin was 31.2%, up 1.2 pts: of every 100 in sales, about 31 is left after running the business.
- Iradimed Corp made $22.5M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 12.6% a year.
- Free cash flow was $17.2M in fiscal 2025, 20.5% of revenue.
- Iradimed Corp returned $15.0M to shareholders in fiscal 2025, 88% of free cash flow. The diluted share count rose 0.5%.
Market cap
$1.1B
P/E
47.9x
Revenue
$83.8M
Net income
$22.5M
Free cash flow
$17.2M
Operating margin
31.2%
Iradimed Corp in 30 seconds · fiscal 2025
Are sales growing?
+14.4%
Yes. Sales grew 14.4% last year.
Does it make a profit?
26.8%
Yes. It keeps 26.8% of every sale as profit.
Does profit turn into cash?
20.5%
Yes. 20.5% of sales ends up as free cash.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
47.9x
One share costs 47.9 times its yearly profit per share.
What Iradimed Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 6, 2026
- Legal name
- IRADIMED CORP
- CIK
- 0001325618
Iradimed Corp · IRMD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $41.8M | $53.3M | $65.6M | $73.2M | $83.8M |
| Revenue growth | 31.8% | 27.5% | 23.0% | 11.7% | 14.4% |
| Gross margin | 76.6% | 77.4% | 76.5% | 76.9% | 76.7% |
| Operating margin | 23.5% | 29.3% | 30.6% | 30.0% | 31.2% |
| Net income | $9.3M | $12.8M | $17.2M | $19.2M | $22.5M |
| Net margin | 22.3% | 24.1% | 26.2% | 26.3% | 26.8% |
| Diluted EPS | $0.74 | $1.02 | $1.35 | $1.50 | $1.75 |
| Cash | |||||
| Cash from operations | $11.3M | $10.0M | $13.5M | $25.6M | $24.9M |
| Capital expenditure | $0.5M | $0.8M | $7.4M | $8.0M | $7.8M |
| Free cash flow | $10.8M | $9.2M | $6.0M | $17.6M | $17.2M |
| FCF margin | 25.8% | 17.3% | 9.2% | 24.1% | 20.5% |
| Dividends paid | — | $12.6M | $13.2M | $13.7M | $15.0M |
| Share count change | 1.2% | 0.4% | 0.7% | 0.5% | 0.5% |
| Debt and strength | |||||
| Cash and short-term investments | $62.0M | $58.0M | $49.8M | $52.2M | $51.2M |
| Shareholders' equity | $72.2M | $73.7M | $71.4M | $86.8M | $94.6M |
| Current ratio | 11.2x | 9.1x | 4.7x | 8.8x | 8.0x |
| Returns and quality | |||||
| Return on equity | 14.0% | 17.6% | 23.7% | 24.3% | 24.8% |
| Return on tangible equity | 13.1% | 17.9% | 25.0% | 23.0% | 24.6% |
| Piotroski F-score | 6 | 5 | 4 | 7 | 5 |
| Altman Z'' | 15.2 | 14.9 | 10.9 | 15.8 | 14.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$18.9M
5 insiders
Of sales under plans
82%
$15.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Iradimed Corp · IRMD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $85.82 a share, the company is worth $1.1B: 47.9 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001325618). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.